Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alasdair Breckenridge

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Pharmacoepidemiology and Drug Safety|March 20, 2003
For the good of the patient: risks and benefits of medicinesAlasdair Breckenridge
British Journal of Clinical Pharmacology|November 26, 2004
The changing scene of the regulation of medicines in the UK. Paper from The Use of Medicines: Regulation & Clinical Pharmacology in the 21st Century Symposium - December 2003Alasdair Breckenridge
Clinical Medicine (London, England)|September 8, 2006
William Withering's legacy--for the good of the patientAlasdair Breckenridge
Nature Reviews. Drug Discovery|November 23, 2006
An audience with... Sir Alasdair Breckenridge. Interview by Joanna OwensAlasdair Breckenridge
Clinical Trials (London, England)|August 13, 2011
Regulatory divergenceAlasdair Breckenridge
British Journal of Clinical Pharmacology|February 25, 2012
Development and delivery of clinical pharmacology in regulatory agenciesAlasdair Breckenridge
Transactions of the Royal Society of Tropical Medicine and Hygiene|July 31, 2003
Debate that "this house believes the essential drug concept hinders the effective deployment of drugs in developing countries". IntroductionAlasdair Breckenridge
Clinical Pharmacology and Therapeutics|August 11, 2018
Regulatory Frameworks in Times of UncertaintyAlasdair Breckenridge
British Journal of Clinical Pharmacology|September 11, 2014
The burden of adverse drug eventsAlasdair Breckenridge
Clinical Pharmacology and Therapeutics|October 23, 2018
Impact of Brexit on UK and EU Drug Regulation and Patient AccessAlasdair Breckenridge, Peter Feldschreiber
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Pharmacoepidemiology and Drug Safety|March 20, 2003
For the good of the patient: risks and benefits of medicinesAlasdair Breckenridge
British Journal of Clinical Pharmacology|November 26, 2004
The changing scene of the regulation of medicines in the UK. Paper from The Use of Medicines: Regulation & Clinical Pharmacology in the 21st Century Symposium - December 2003Alasdair Breckenridge
Clinical Medicine (London, England)|September 8, 2006
William Withering's legacy--for the good of the patientAlasdair Breckenridge
Nature Reviews. Drug Discovery|November 23, 2006
An audience with... Sir Alasdair Breckenridge. Interview by Joanna OwensAlasdair Breckenridge
Clinical Trials (London, England)|August 13, 2011
Regulatory divergenceAlasdair Breckenridge
British Journal of Clinical Pharmacology|February 25, 2012
Development and delivery of clinical pharmacology in regulatory agenciesAlasdair Breckenridge
Transactions of the Royal Society of Tropical Medicine and Hygiene|July 31, 2003
Debate that "this house believes the essential drug concept hinders the effective deployment of drugs in developing countries". IntroductionAlasdair Breckenridge
Clinical Pharmacology and Therapeutics|August 11, 2018
Regulatory Frameworks in Times of UncertaintyAlasdair Breckenridge
British Journal of Clinical Pharmacology|September 11, 2014
The burden of adverse drug eventsAlasdair Breckenridge
Clinical Pharmacology and Therapeutics|October 23, 2018
Impact of Brexit on UK and EU Drug Regulation and Patient AccessAlasdair Breckenridge, Peter Feldschreiber
Pageof 5